[Huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- (HTT) is a large, multifunctional protein of approximately 350 kDa encoded by the HTT gene on chromosome 4p16.3. [The landmark discovery in 1993 by the Huntington's Disease Collaborative Research Group of a CAG [trinucleotide repeat expansion[/mechanisms/[trinucleotide-repeat-expansion[/mechanisms/[trinucleotide-repeat-expansion[/mechanisms/[trinucleotide-repeat-expansion[/mechanisms/[trinucleotide-repeat-expansion--TEMP--/mechanisms)--FIX-- in HTT as the cause of [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- (HD) transformed our understanding from a clinical syndrome to a molecularly defined genetic disorder ([The HD Collaborative Research Group, 1993)190585-E)). HTT is one of the largest [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins in the human proteome at 3,144 amino acids and serves as a critical scaffold for intracellular signaling, vesicular transport, and transcriptional regulation across many neuronal and non-neuronal tissues 18).
Huntingtin is ubiquitously expressed but is most abundant in the brain, particularly in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- of the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- 290346-1)). The protein is essential for normal embryonic development; complete knockout of HTT is embryonic lethal in mice by day E7.5 3). In the adult brain, wild-type huntingtin plays critical roles in vesicle trafficking, transcriptional regulation, [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--, neurotrophic support, and synaptic function. A 2024 study showed that global HTT knockout in adult mice leads to fatal neurodegeneration, confirming that huntingtin remains essential throughout life 11).
| Property |
Value |
| Gene |
HTT (chromosome 4p16.3) |
| Protein length |
3,144 amino acids |
| Molecular weight |
~350 kDa |
| UniProt ID |
P42858 |
| Normal polyQ repeat |
10-35 CAG repeats |
| Reduced penetrance |
36-39 CAG repeats |
| Full penetrance |
>=40 CAG repeats |
¶ Protein Domains and Architecture
Huntingtin has a complex multi-domain architecture organized around HEAT (Huntingtin, Elongation factor 3, protein phosphatase 2A, TOR1) repeat motifs that fold into superhelical solenoid structures 7):
- N17 domain (residues 1-17): An amphipathic alpha-helix that is evolutionarily conserved and regulates membrane association, nuclear localization, and aggregation. Post-translational modifications (PTMs) in N17 profoundly alter toxicity and aggregation state 8).
- Polyglutamine (polyQ) tract: The expanded CAG-encoded glutamine stretch that causes disease when >=36 repeats. The polyQ tract adopts beta-hairpin conformations in fibrillar aggregates, as revealed by cryo-EM 9).
- Polyproline region: Located immediately C-terminal to the polyQ tract; modulates aggregation kinetics and protein-protein interactions.
- HEAT repeat clusters: Multiple HEAT repeat regions spanning the protein form a solenoid scaffold that mediates diverse protein-protein interactions, including with HAP1, dynactin, and transcription factors.
- Nuclear localization signal (NLS) and nuclear export signal (NES): Enable bidirectional nucleocytoplasmic shuttling.
Huntingtin undergoes numerous PTMs that regulate its function, localization, and toxicity:
- Phosphorylation: Serine 13 and serine 16 in the N17 domain are protective; their phosphorylation reduces aggregation and toxicity. Threonine 3 (T3) phosphorylation is decreased in HD, and restoring it modulates mutant HTT conformation 10).
- SUMOylation: SUMO modification of lysines in the N17 domain increases aggregation and toxicity.
- Acetylation: Acetylation at K444 promotes autophagic clearance of mutant HTT.
- Palmitoylation: Palmitoylation by HIP14 regulates membrane association and vesicle trafficking.
- Proteolytic cleavage: Cleavage by [caspases[/entities/[caspases[/entities/[caspases[/entities/[caspases[/entities/[caspases--TEMP--/entities)--FIX-- (particularly caspase-6 at D586), [calpains[/entities/[calpains[/entities/[calpains[/entities/[calpains[/entities/[calpains--TEMP--/entities)--FIX--, and other proteases generates N-terminal fragments containing the expanded polyQ that are highly toxic and aggregate-prone.
¶ Vesicle Trafficking and Axonal Transport
Wild-type huntingtin serves as a molecular scaffold for intracellular transport, associating with vesicles and organelles along microtubules. It interacts with huntingtin-associated protein 1 (HAP1) and the dynactin complex to regulate both anterograde and retrograde transport of cargoes, including BDNF-containing vesicles, mitochondria, and endosomal compartments 4). This transport function is especially critical for maintaining the health of long-range projection [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- and [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--.
Huntingtin acts as a scaffold for transcription factors including RE1-silencing transcription factor (REST/NRSF), NCoR, CtBP, and p53, modulating expression of [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes involved in neuronal survival, synaptic plasticity, and [BDNF[/entities/[bdnf[/entities/[bdnf[/entities/[bdnf[/entities/[bdnf--TEMP--/entities)--FIX-- production 5). Wild-type HTT sequesters REST in the cytoplasm, preventing it from silencing neuronal genes in the nucleus.
¶ Anti-Apoptotic and Neuroprotective Roles
Normal huntingtin protects against [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX-- through multiple mechanisms:
- Inhibiting caspase-3 and caspase-9 activation
- Promoting mitochondrial integrity
- Modulating p53 function
- Protecting against [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- via regulation of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor] signaling
Huntingtin facilitates the transcription and axonal transport of brain-derived neurotrophic factor (BDNF), a critical survival factor for medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--. Wild-type HTT binds REST in the cytoplasm, promoting BDNF transcription; this function is disrupted in HD 6).
¶ Autophagy and Proteostasis
Huntingtin plays a direct role in selective autophagy, interacting with [p62/SQSTM1[/proteins/[p62-sqstm1[/proteins/[p62-sqstm1[/proteins/[p62-sqstm1[/proteins/[p62-sqstm1--TEMP--/proteins)--FIX--, ULK1, and other autophagy machinery to facilitate clearance of damaged organelles and aggregated proteins 16).
The mutant huntingtin protein (mHTT) with expanded polyQ tract (>=36 repeats) causes [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- through both toxic gain-of-function and partial loss of normal function:
¶ Protein Aggregation and Phase Separation
mHTT forms intracellular aggregates (inclusion bodies) enriched in N-terminal fragments containing the expanded polyQ tract. Cryo-EM studies reveal that polyQ fibrils adopt a beta-hairpin core structure forming planar beta-sheets 9). Recent work highlights that HTT undergoes liquid-liquid phase separation (LLPS), and expanded polyQ disrupts this process, converting liquid condensates into solid aggregates 15). Aggregates sequester essential cellular proteins including ubiquitin, chaperones, and transcription factors.
mHTT disrupts transcription through multiple mechanisms:
- REST/NRSF derepression: mHTT fails to sequester REST in the cytoplasm, leading to nuclear REST accumulation and silencing of neuronal genes including BDNF
- Sp1/TAFII130 interference: mHTT binds and sequesters transcription factors
- Chromatin remodeling: Altered [histone modifications[/entities/[histone-modifications[/entities/[histone-modifications[/entities/[histone-modifications[/entities/[histone-modifications--TEMP--/entities)--FIX-- and [HDAC] recruitment
- RNA Pol II impairment: Disrupted transcription elongation
Key affected pathways include BDNF expression, [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- signaling, mitochondrial biogenesis, and [neuronal survival] 5).
mHTT impairs mitochondrial function through:
- Decreased PGC-1alpha expression, a master regulator of mitochondrial biogenesis
- Impaired [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- (fusion/fission balance)
- Reduced respiratory chain complex II and III activity
- Disrupted calcium handling and increased susceptibility to calcium-induced permeability transition
- Increased production of [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
A 2024 study using human [brain organoids[/technologies/[brain-organoids[/technologies/[brain-organoids[/technologies/[brain-organoids[/technologies/[brain-organoids--TEMP--/technologies)--FIX-- showed that mHTT disrupts CHCHD2-mediated mitochondrial metabolism during neurodevelopment, suggesting pathology begins far earlier than clinical onset 12).
¶ Impaired Autophagy and Proteostasis
mHTT disrupts cellular [protein quality control]:
- Impairs cargo recognition in selective autophagy (autophagosomes form but are often empty)
- Disrupts lysosomal function
- Overwhelms the [ubiquitin-proteasome system[/cell-types/[ubiquitin-proteasome-system[/cell-types/[ubiquitin-proteasome-system[/cell-types/[ubiquitin-proteasome-system[/cell-types/[ubiquitin-proteasome-system--TEMP--/cell-types)--FIX--
- Creates a vicious cycle of proteostatic stress as aggregates accumulate
mHTT sensitizes [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, particularly medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--, to excitotoxic cell death:
- Altered [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor] subunit composition and trafficking (increased GluN2B surface expression)
- Increased intracellular calcium influx
- Activation of calpains and other calcium-dependent proteases
- Synergistic interaction with [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--
mHTT reduces neurotrophic support to [striatal] [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--:
- Decreased BDNF gene transcription (REST derepression)
- Impaired BDNF vesicle transport along corticostriatal axons
- Reduced TrkB receptor signaling in target [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
This corticostriatal BDNF deficit is a major contributor to the selective vulnerability of medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in HD 6).
¶ CAG Repeat Length and Disease Onset
The length of the CAG repeat expansion is the primary determinant of disease onset and severity:
| CAG Repeats |
Classification |
Clinical Outcome |
| 6-26 |
Normal |
No disease risk |
| 27-35 |
Intermediate |
No disease, possible meiotic instability |
| 36-39 |
Reduced penetrance |
May or may not develop HD |
| 40-59 |
Full penetrance |
Adult-onset HD (typically 35-50 years) |
| >=60 |
Full penetrance |
Juvenile-onset HD (<20 years) |
Age of onset correlates inversely with repeat length, though genetic modifiers (particularly DNA mismatch repair genes such as MSH3, PMS1, PMS2, and MLH1) also strongly influence onset 14). Somatic expansion of the CAG repeat, particularly in [striatal] [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, is now recognized as a critical driver of disease progression.
¶ Biomarkers and Disease Monitoring
- Mutant huntingtin (mHTT) in CSF: Detectable by ultrasensitive immunoassay; correlates with disease stage
- [Neurofilament light chain[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein--TEMP--/proteins)--FIX-- (NfL): Elevated in CSF and plasma; tracks neurodegeneration
- [Neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging--TEMP--/diagnostics)--FIX--: Striatal and cortical volume loss on MRI; emerging PET tracers for mHTT aggregates
- Digital biomarkers: Wearable sensor data capturing motor and cognitive decline
The most promising therapeutic paradigm targets reduction of mHTT expression:
- Antisense oligonucleotides (ASOs): Tominersen (formerly IONIS-HTT_Rx/RG6042) was the first HTT-lowering ASO to enter phase III trials but was halted in 2021 due to unfavorable risk-benefit. Lessons learned are informing next-generation allele-selective ASOs that spare wild-type HTT 13).
- RNA interference (RNAi): AMT-130 (uniQure), a one-time AAV5-delivered miRNA targeting HTT, showed dose-dependent mHTT lowering in CSF and potential slowing of functional decline in phase I/II trials (Unidata from CHDI 2024 conference).
- CRISPR-based approaches: Emerging preclinical strategies for permanent inactivation of the expanded HTT allele.
The discovery that DNA mismatch repair genes drive somatic CAG expansion has opened a new therapeutic axis. Inhibitors of MSH3 are in preclinical development to slow or prevent somatic repeat expansion in [striatal] [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- 14).
- Motor symptoms: Tetrabenazine and deutetrabenazine (VMAT2 inhibitors) for chorea; FDA-approved
- Psychiatric symptoms: SSRIs/SNRIs for depression; atypical antipsychotics for psychosis and agitation
- Cognitive symptoms: No approved [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments; [cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX-- have limited efficacy
- Small molecule splicing modulators: Branaplam (originally developed for SMA) was found to lower HTT but clinical development was halted
- Protein clearance enhancers: Strategies to boost [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- and proteasomal degradation of mHTT
- Neuroprotective agents: Targeting mitochondrial function, [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX--, and [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--
- [Clinical Trials Index[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials
The study of Huntingtin Protein (Htt) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Huntingtin protein (HTT) is essential for normal neuronal development and function, with its mutation causing Huntington's disease through a toxic gain-of-function mechanism. The expanded CAG repeat in the HTT gene leads to mutant huntingtin (mHTT) protein that forms aggregates, disrupts cellular transport, impairs mitochondrial function, and alters gene transcription.
Therapeutic strategies targeting HTT include:
- Gene silencing: ASOs and RNAi approaches to reduce mHTT expression
- Protein modulation: Enhancing autophagy and HTT clearance
- Function restoration: Targeting downstream pathways affected by mHTT
Recent clinical trials have focused on allele-selective ASOs that preferentially silence the mutant allele while sparing wild-type HTT, which is essential for normal cellular function. The challenge of delivering therapeutics to the striatum and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, regions most affected in HD, remains an active area of research.
Understanding huntingtin's normal functions in development, neuronal survival, and synaptic plasticity continues to inform therapeutic strategies. The goal of disease modification through HTT-lowering approaches represents the most advanced therapeutic pathway toward effective HD treatment.
- [The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes. Cell. 1993;72(6):971-983. [DOI][1])
- [DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. 1995;14(5):1075-1081. [DOI][2])
- [Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's Disease gene homolog Hdh. Science. 1995;269(5222):407-410. [DOI][3]
- [Gunawardena S, Goldstein LS. Polyglutamine [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases/diseases] and transport problems: deadly traffic jams on neuronal highways. Arch Neurol. 2005;62(1):46-51. [DOI][4]
- [Cha JH. Transcriptional signatures in Huntington's Disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):78-92. [DOI][5]
- [Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35(1):76-83. [DOI][6]
- [Guo Q, Bin H, Cheng J, et al. The cryo-EM structure of huntingtin. Nature. 2018;555(7694):117-120. [DOI][7]
- [Bravo-Arredondo JM, et al. The N17 domain of huntingtin as a multifaceted player in Huntington's Disease. Front Mol Biosci. 2024;11:1527313. [DOI][8]
- [Hoop CL, Lin HK, Kar K, et al. Structural basis of huntingtin fibril polymorphism revealed by cryogenic electron microscopy of exon 1 HTT fibrils. J Am Chem Soc. 2024;144:10560-10569. [DOI][9]
- [Cariulo C, Azzollini L, Veber D, et al. Phosphorylation of huntingtin at residue T3 is decreased in Huntington's Disease and modulates mutant huntingtin protein conformation. Proc Natl Acad Sci USA. 2017;114(50):E10809-E10818. [DOI][10]
- [Dietrich P, et al. Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas. Life Sci Alliance. 2024;7(9):e202402571. [DOI][11]
- [Faravelli I, et al. Mutant huntingtin impairs neurodevelopment in human brain organoids through CHCHD2-mediated neurometabolic failure. Nat Commun. 2024;15:6942. [DOI][12]
- [Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington's Disease. N Engl J Med. 2019;380(24):2307-2316. [DOI][13]
- [Genetic Modifiers of Huntington's Disease (GeM-HD Consortium. CAG repeat not polyglutamine length determines timing of Huntington's Disease onset. Cell. 2019;178(4):887-900. [DOI][14]
- [Peskett TR, Rau F, O'Driscoll J, et al. A liquid to solid phase transition underlying pathological huntingtin exon1 aggregation. Mol Cell. 2018;70(4):588-601. [DOI][15]
- [Rui YN, Xu Z, Patel B, et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat Neurosci. 2015;18(10):1430-1436. [DOI][16]
- [Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. 2012;342(3):619-630. [DOI][17]
- [Saudou F, Bhide PG. Huntingtin protein in health and Huntington's Disease: molecular mechanisms, pathology, and therapeutic strategies. Ageing Res Rev. 2024;105:102678. [DOI][18]
- [Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575-621. [DOI][19]